Kevin Laliberte

Kevin Laliberte is a declared insider of Dova Pharmaceuticals Inc., with filings sourced from SEC (Form 4). The record holds 8 filings, for trades running from 5 July 2017 to 12 November 2019.

In open-market terms, that means 1 purchase worth €93k on one side and 5 sales worth €187k on the other. On balance, insiders were net sellers of €94k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. So far in 2019, the count stands at no purchases and 5 sales.

Most recently, on 12 November 2019, the filings show a transaction in Dova Pharmaceuticals Inc. The most recent open-market purchase was published on 7 July 2017, 3,392 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.